ACADIA PHARMACEUTICALS INC. Share-based Payment Arrangement, Amount Capitalized
ACADIA PHARMACEUTICALS INC. (ACAD) reported Share-based Payment Arrangement, Amount Capitalized of $57.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-02.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement
us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount · last filed 2019-05-02
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, amount capitalized for the quarter ending 2019-03-31 was $57.00K.
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, amount capitalized for the quarter ending 2018-12-31 was -$185.00K.
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, amount capitalized for the quarter ending 2018-09-30 was -$292.00K, a 257.84% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, amount capitalized for the quarter ending 2018-06-30 was -$113.00K.
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, amount capitalized for fiscal 2018 was -$748.00K.
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, amount capitalized for fiscal 2017 was -$61.00K, a 107.01% decline from fiscal 2016.
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, amount capitalized for fiscal 2016 was $870.00K.
| Period end | Share-based Payment Arrangement, Amount Capitalized 3 month | Share-based Payment Arrangement, Amount Capitalized 6 month | Share-based Payment Arrangement, Amount Capitalized 9 month | Share-based Payment Arrangement, Amount Capitalized 12 month |
|---|---|---|---|---|
| 2019-03-31 | $57.00K 10-Q · filed 2019-05-02 | -$128.00K derived: sum of 2 quarters · filed 2019-05-02 | -$420.00K derived: sum of 3 quarters · filed 2019-05-02 | -$533.00K derived: sum of 4 quarters · filed 2019-05-02 |
| 2018-12-31 | -$185.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$477.00K derived: sum of 2 quarters · filed 2019-02-27 | -$590.00K derived: sum of 3 quarters · filed 2019-02-27 | -$748.00K 10-K · filed 2019-02-27 |
| 2018-09-30 | -$292.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$405.00K derived: sum of 2 quarters · filed 2018-11-06 | -$563.00K 10-Q · filed 2018-11-06 | -$908.00K derived: sum of 4 quarters · filed 2019-05-02 |
| 2018-06-30 | -$113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$271.00K 10-Q · filed 2018-08-08 | -$616.00K derived: sum of 3 quarters · filed 2019-05-02 | -$431.00K derived: sum of 4 quarters · filed 2019-05-02 |
| 2018-03-31 | -$158.00K 10-Q · filed 2019-05-02 | -$503.00K derived: sum of 2 quarters · filed 2019-05-02 | -$318.00K derived: sum of 3 quarters · filed 2019-05-02 | |
| 2017-12-31 | -$345.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$160.00K derived: sum of 2 quarters · filed 2019-02-27 | -$61.00K 10-K · filed 2019-02-27 | |
| 2017-09-30 | $185.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $284.00K 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $99.00K 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | $72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $515.00K derived: sum of 2 quarters · filed 2019-02-27 | $870.00K 10-K · filed 2019-02-27 | |
| 2016-09-30 | $443.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $798.00K 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $355.00K 10-Q · filed 2017-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |